John Bushweller, PhD, Professor of Molecular Physiology and Biological Physics at UVA and co-leader of the Cancer Biology Program at UVA Comprehensive Cancer Center, is collaborating with C-Further, an international consortium dedicated to advancing new therapies for childhood cancers, to develop a new treatment option that targets a transcription factor that fuels Ewing Sarcoma. The goal is a new drug that could offer better outcomes with less toxicity. Read more: https://ww

Following induction treatment for high-risk neuroblastoma, more than half of children experience cisplatin-induced hearing loss (CIHL), according to research published in JCO Clinical Advances. Read more: https://www.cancertherapyadvisor.com/news/cisplatin-hearing-loss-pediatric-high-risk-neuroblastoma/

Nagourney Cancer Institute and Metabolomycs with the FibroFighters Foundation showed fibrolamellar cancers appear to arise through changes in cellular metabolism. Read more: https://finance.yahoo.com/sectors/healthcare/articles/breakthrough-highly-lethal-childhood-cancer-140000323.html

"The biology has been pointing in this direction for a decade. The regulatory architecture is in place. The incentives exist. What happens in the next generation of molecularly targeted oncology programs will depend on whether protocol teams treat that nine-year-old’s NTRK fusion as a scheduling problem for post-approval — or as the enrollment criterion she was always supposed to be." Read more: https://www.clinicaltrialvanguard.com/opinion/pediatric-oncology-keeps-getting-tr

Healthy lifestyles can reduce the risk of cardiovascular disease and other complications in childhood cancer survivors. These are the findings of two new international studies. Read more: https://www.eurekalert.org/news-releases/1130093

Physical functioning is significantly diminished by intensive management of childhood posterior fossa brain tumors (PFTs) and correlates with survivors’ neurologic treatment burdens, suggests research presented at the 51st Annual ONS Congress in San Antonio, Texas. Read more: https://www.oncologynurseadvisor.com/reports/brain-tumors-functional-challenges-long-term-pediatric-pft/

In a study published in Cell Death & Disease, researchers led by Blanco identified a potential way to reduce relapse in medulloblastoma by targeting the tumor cells most likely to survive treatment and drive regrowth. Read more: https://www.news-medical.net/news/20260526/Scientists-target-root-of-relapse-in-aggressive-childhood-brain-tumors.aspx

A team of scientists has uncovered new evidence that some cases of a subtype of childhood leukaemia may develop before birth, shedding light on how the disease evolves over time. Read more: https://www.icr.ac.uk/about-us/icr-news/detail/new-study-traces-rare-form-of-childhood-leukaemia-back-to-before-birth

A study by researchers at the University of Birmingham has identified a new biomarker for response to a specific cancer therapy, treating children with Ewing Sarcoma and other tumour types. Read more: https://www.eurekalert.org/news-releases/1129340

Pediatric Non-Hispanic Black patients with acute myeloid leukemia (AML) are at increased risk for acute kidney injury (AKI) during treatment, according to research published in Cancer Medicine. Read more: https://www.cancertherapyadvisor.com/news/pediatric-non-hispanic-black-aml-all-patients-acute-kidney-injury/